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significant difference with unaffected controls. However, the IHPS associated risk SNP rs1933683 had 48 a significantly higher incidence (OR 3.29, p=0.009). 49
Although the genetic variation in likely candidate genes as well as the predisposing locus near 50 BARX1 (rs1933683) suggest a genetic component, it does not fully explain the abnormalities seen in 51 these patients. Therefore, we hypothesize that a combination of high impact genetic, mechanical and 52 environmental factors together can shift the balance to abnormal development. 53 INTRODUCTION whole exome sequencing (WES) was obtained for 15 patients. Several phenotypical characteristics 122 stood out in this EA/IHPS cohort: a sacral dimple was present in seven patients (25.9%), anomalies of 123 the vertebrae or ribs in eight patients (29.7%) and genitourinary anomalies in six patients (22.2%) of 124 which two patients (7.4%) had hypospadias. Four patients (14.8%) had three or more anomalies 125 within the VACTERL spectrum (Solomon, 2011) . A full phenotypical description of the 27 EA/IHPS 126 patients is given in Table 2 . cohort. All rare CNVs, classified as VUS or (likely) deleterious are described in Table S1 . 140 141
Exome sequence analysis 142
Sequencing resulted in at least 5 Giga-bases of raw sequence data with an average coverage of 70X 143 and 90% of target bases covered over 20X. Quality of the sequence data is listed in Table S2 . As none 144 of the parents of the 15 investigated patients were affected we first considered dominant de novo 145 and recessive modes of inheritance. 146
We could not identify de novo pathogenic variation in main EA and IHPS disease genes (Brosens et 147 al., 2014 , Peeters et al., 2012 . Subsequently, we searched for possible de novo mutations exome 148 wide. For this, we focused on putative deleterious ultra-rare protein coding or splice site variants 149 artifacts. Furthermore, we could not confirm the segregation of 15 mutations due to lack of parental 153 DNA. We determined the segregation of all ultra-rare variants predicted to be of unknown 154 significance (VUS, n=37) or (likely) deleterious (n=23). All putative deleterious variants tested proved 6 Considering a recessive mode of inheritance, we searched for genes with homozygous or 157 compound heterozygous variants. Six variants in three genes (FLNC, ATP6V0A1 and FAM46A) fitted a 158 putative compound heterozygous model, two genes (KCNN3 and VDAC3) had homozygous variants 159 and two genes (MID2 and SH3KBP1) had variants on chromosome X in a male patient. All variants 160 were predicted to be likely deleterious or VUS and intolerant to missense variants (Z-score ≥3) or loss 161 of function variants (PLI or PLIrec ≥0.9). With segregation analysis, we could confirm the compound 162 heterozygous mode of inheritance of the variant in the FAM46A gene in patient SKZ_2023 and the 163 maternally inherited X-linked variant in the SK3KBP1 gene in patient SKZ_1260. The other recessive 164 candidate genes could not be validated due to technical difficulties (and are likely sequencing 165 artifacts) or due to lack of parental DNA. None of the recessive candidate genes were affected twice 166 or more in this cohort. All predicted deleterious variants were submitted to the ClinVar database 167 https://www.ncbi.nlm.nih.gov/clinvar/ (Landrum et al., 2014). 168
We inspected the CN profiles from WES-CN and SNP-array for partial overlap with genes affected 169 by heterozygous variant predicted to be deleterious in (recessive) loss of function intolerant or 170 missense intolerant genes (n=48) and could not detect unmasking of a recessive mutation by a CNV. 171
Ultra-rare variants (n=78), X-linked or recessive variants are depicted in Table S4 
Pathway enrichment analysis of genes affected by rare variants 175
When looking at the selected protein altering variants (Z-score ≥3, n=44) or loss of function 176 intolerant (PLI ≥0.9, n=4), two relevant pathways were significantly enriched (p-value <1x10 -5 ): 177 proliferation and differentiation of smooth muscle cells (INSR, ITGB1, NOTCH1, TCF4, PDE4D, TERT, 178 ANKRD17, DICER1) and self-renewal of satellite cells (ITGB1, NOTCH1). 179 180
Variant prioritization using different in silico tools 181
We prioritized all rare variants with three in silico tools (see Methods section). Fifty-four variants in 182 Table  185 S3. 186
Additionally, we found variants in the same gene in multiple patients ( Fig. 1 ). Of these 116 genes 187 (VUS=87, likely deleterious=30), 36 genes were found in ≥3 patients of which six genes were present 188 in more than five patients (CNTN2, DSPP, NOTCH4, PRRC2A, SEC16B, ZNF717). Four (AMBRA1, 189 7 192
Gene burden analysis 193
An exome wide gene burden analysis showed ten genes which were enriched for rare putatively 194 deleterious variation compared to the 1000 Genomes project phase 3 samples. The results are 195 shown in Table 3 . There were no genes with more than two distinct variants. Each variant was 196 observed only once. A second burden test -only evaluating genes from developmental important 197 pathways and known disease genes -showed no significant difference between our 15 patients and 198 a control group of 44 healthy individuals, who were sequenced in a previous study (Table 4) . Also, 199 the number of putative deleterious variants between these two groups was not significantly different 200 (Table 5) . Unfortunately, a burden test comparing the variant profiles of these genes between the 201 patients and their parents was not possible since no WES data of the parents was available. 202
Expression of main candidate gene during development 203
With public micro-array transcriptome data we evaluated which genes were upregulated at a specific 204 time-point in the foregut, esophagus or pyloric sphincter and used the output as an indicator of gene 205 expression (see Methods section and Table S5 ). Of the genes classified as VUS or likely deleterious in 206 our exome sequencing results, 28 genes were upregulated in both the foregut or esophagus as well 207 as the pyloric sphincter: ADAMTSL4, AGRN, ANKRD29, ARHGAP29, CAMTA1, CDHR5, CNTN2, 208 COL11A1, DNAJC11, HIVEP3, HMCN1, HMGCS2, HSPG2, ITGB3BP, LDB3, MYOF, NKX2-3, NUP133, 209 PCSK9, PKN2, PRDM16, PUM1, RET, SEC16B, SERINC2, TMEM82, VPS13D and ZBTB7B. 210 Unfortunately, none of the genes enriched in our burden analysis were differentially expressed in 211 mice foregut between E8.5 and E16.5. Seven out of 116 genes with putative deleterious variants in 212 more than one patient were differentially expressed in mice foregut: Adamtsl4 at E8.5, E14.5 and 213 E16.5; Ankrd26 at E14.5; Cntn2 at E8.5, E15.5 and E18.5; Hspg2 at E8.25, E8.5, E14.5 and E18.5; 214
Kcnn3 at E8.5 and E15.5; Ldb3 at E8.5, E14.5 and E15.5; Sec16b at E8.5, E14.5 and E16.5. Of the top 215 candidate genes in the manual burden analysis (see Table 4 and Table S6 ) only Ret was differentially 216 expressed in mice at E8.25, E8.5, E11.5, E14.5, E15.5, E16.5 and E18.5. 217
218

Detection of common SNPs associated with IHPS 219
Determination of the risk allele frequency of four loci highly associated with IHPS (rs11712066, 220 rs573872, rs29784 and rs1933683 near genes MBNL1, NKX2-5 and BARX1, respectively) revealed a 221 significantly higher incidence of rs1933683 in our EA/IHPS cohort compared to the population 222 frequency (OR 3.29 (95% CI 1.27-8.56), p=0.009, see Table S7 ). The risk allele frequency of the other 223 risk loci was not significantly different from the normal population. We did not detect rare putatively DISCUSSION 226 We hypothesized that the increased prevalence of IHPS in patients with EA compared to the 227 prevalence of IHPS in the normal population was due to shared CNVs or protein coding alterations in 228 a specific gene, or due to genetic disturbances in genes of shared biological networks during 229 development. As mentioned earlier, both EA and IHPS are variable features in specific genetic 230 syndromes (Table 1) . Therefore, to find genetic aberrations that contribute to EA/IHPS we initially 231 searched for pathogenic alterations in known EA or IHPS associated genes (Table S6) . 232
233
There are no pathogenic changes in known disease genes 234
As all parents were unaffected, we started this study by focusing on de novo, recessive or X-linked 235 changes affecting these known disease genes. However, we could not identify deleterious protein 236 coding alterations, exonic gains or losses or larger CNVs affecting these genes. This is in line with 237 previous studies in which limited causal changes could be detected in patients with EA and 238 2017). Unfortunately, we did not identify any de novo mutations or de novo CNVs. None of the 247 identified inherited rare CNVs overlapped in these patients. We could confirm the presence of a 248 compound heterozygous variant in FAM46A in one patient and an X-linked variant in SH3KBP1 in 249 another patient. However, FAM46A and SH3KBP1 are not known to be associated with the 250 gastrointestinal or respiratory tract and were not differentially expressed at the time points 251 important for foregut morphogenesis. These findings made us conclude that neither a dominant nor 252 a recessive model can explain the combination of EA and IHPS in these patients. 253
254
The coding sequences of genes crucial in esophageal and pyloric sphincter formation are affected 255 Subsequently, we focused on genes involved in foregut development. Literature research together 256 with data of previous expression studies provided an overview of genes important for foregut 257 development ( Fig. 2) . 258
The development of the foregut is most studied in mouse models. In mice, early foregut 259 formation starts with Foxa2 stimulation of the anterior endoderm at E8.0 (Heath, 2010) Given the described importance of these genes in normal development, we hypothesized that 278 variations in multiple genes important for foregut morphogenesis might explain the higher incidence 279 of IHPS in patients with EA. We compared a selection of genes -known to be important for foregut 280 morphogenesis or syndromatically associated with EA or IHPS -between the patients and the 281 healthy controls (Table 4, Table S6 ). Interestingly, in TNXB (NM_019105.6:c.4444G>A, There is no high frequency burden of rare variants 289
Given the limited number of samples, we will only detect a gene burden if it is large and has a high 290 impact. We compared the total rare and ultra-rare variant burden of putative deleterious variants in 291 all genes. The number of ultra-rare variants was slightly higher in the patient group compared to the with more variants compared to those seen in the 1000 Genome cohort, two variants were predicted 294 to be deleterious (Table 3) . Unfortunately, they did not show any overlap with the results of the 295 expression analysis or candidate genes selected from the literature. Therefore, these variants are not 296 likely to explain the increased incidence of IHPS in EA patients or EA/IHPS development. A rare 297 variant burden might exist but we could not detect it due to limited sample size and/or focus on 298 known candidate genes. 299
300
Of all the protein coding changes classified as VUS or higher (Table S4 ; Table S8 ), 116 genes were 301 affected with a variant in more than one patient ( Fig. 1) . Seven of these genes (ADAMTSL4, 302 ANKRD26, CNTN2, HSPG2, KCNN3, LDB3, SEC16B) were differentially expressed in the developing 303 foregut, esophagus or pyloric sphincter in mice between E8.25 and E16.5. However, none of these 304 genes could explain the combination of EA and IHPS within a patient based on their function; none of 305 these genes is known to be associated with the gastrointestinal or respiratory tract. Furthermore, 306 most variants had a population frequency above the prevalence of EA/TEF. If these variants are 307 highly penetrant, they would not be the likely cause. Increasing sample sizes (drastically) would allow 308 an analysis going beyond known intolerant genes, allow us to consider reduced penetrance and 309 potentially identify a shared genetic etiology. 310 311
Known common variants associated with IHPS development could have an impact in some patients 312
Since certain SNPs have been identified with GWAS to be highly associated with IHPS, we wondered 313 if these known common haplotypes could also play a role in the higher incidence of IHPS in patients 314 with EA. In our cohort, we found a significantly higher incidence of the risk loci rs1933683 compared 315 to the population frequency (Table S7 ). Three patients were homozygous for the risk allele and have 316 a substantially increased risk for IHPS development. The common risk haplotype might therefore 317 impact IHPS development in some of the IHPS patients. However, further research is needed to 318 confirm the impact of this haplotype in a larger EA and EA/IHPS population. 319
Possible contribution of non-genetic factors 320
All the data presented so far made us conclude that dominant de novo variations in possible disease 321 causing genes do not play a role in our cohort. Recessive inheritance cannot totally be excluded, 322
although our results are not suggestive for this mode of inheritance. We did identify in all patients 323 putative disease-causing variants. Nevertheless, as all parents from whom these variants were 324 inherited were not affected, these variants could contribute but not cause the disease. Previous 325 studies suggested the contribution of non-genetic factors as an explanation for the combined 326 occurrence of EA and IHPS. 327
Could IHPS be an acquired condition related to surgery or treatment of EA? 328
The overrepresentation of IHPS in EA patients made us wonder if IHSP could also be the result of the 329 atresia itself, potentially as a result of the surgical procedure to correct the atresia or the result of 330 treatment. Previous studies also mentioned vagal nerve lesions, a gastrostomy and transpyloric 331 feeding tubes as possible causes for an increased incidence of IHPS after correction of EA (Ilhan et al., 332 2018) . IHPS has been suggested to be a neuromuscular disorder with the involvement of smooth 333 muscle cells, interstitial cells of Cajal and the enteric nervous system. The hypertrophy is suggested 334 to be the result of discoordinated movements of the pyloric sphincter and the contractions of the on the cause and other specific clinical risk factors for patients with EA should be considered, e.g. the 343 late start of oral feeding or the long-term feeding through a tube instead of drinking themselves. 344 345
Models for EA/IHPS disease etiology 346
Since we hypothesized that genetic defects, disturbing foregut morphogenesis, would be responsible 347 for the combination of EA/IHPS, we started with the thought of a (monogenetic) syndromic model. 348
However, we have not been able to find a central gene impacted in most patients which can explain 349 the increased prevalence of IHPS in patients with EA. An as yet unknown syndrome is unlikely since 350 we have not found de novo (as all parents are unaffected) or shared high impact variants in the same 351 gene multiple patients. However, we cannot exclude de novo mutations which have been seen in the 352 GnomAD exomes or genomes, nor did we look beyond the coding part of our genome. 353 Furthermore, we have detected inherited rare variants in candidate genes and genes affected 354 more than once by variants with a low (unaffected) population frequency. Therefore, we cannot 355 exclude a genetic component. Another option is that, although the combination of EA and IHPS could expressivity). The latter would fit the results in this study; maybe we did have detected variants but 390 have we failed to interpret them correctly as parents were seemingly unaffected and/or the variant 391 frequency can be higher in unaffected controls to be of relevance in patients. Mechanical or 392 environmental factors could have made the difference in shifting the balance. All together the 393 burden model is a plausible explanation for the disease development. 394
395
Last, we hypothesize a slippery slope model (Fig. 3B ). In this model, the burden of low impact genetic 396 variants and environmental disturbances alone does not impact the balance seen in the seesaw 397 model unless it crosses a certain threshold. Moreover, we hypothesize that the protective 398 mechanisms (e.g. compensatory mechanisms) during development are very strong, making it really 399 difficult to shift the balance. Most fetuses do not develop any malformations despite the combined 400 genetic and environmental burden or do not survive. But once the threshold is reached, the balance 401 is immediately greatly disrupted and often multiple organ systems are affected. This model fits with 402 the phenotypical results in this study since four patients (14.8%) had three or more anomalies within 403 the VACTERL spectrum. In this model there is a high tolerance for low impact genetic variation and 404 only high impact variation (aneuploidies, exposure to toxic substances, pathogenic changes in 405 developmental crucial genes) shifts the balance. When the balance is disturbed, it shifts drastically. 406
We did not detect high impact changes responsible for the EA/IHPS combination. As parents are 407 unaffected it is (in this model) unlikely that inherited variants impact disease development, nor 408 would variants which are seen in the (unaffected) population controls. 409 410
Limitations 411
Not finding any positive correlation between DNA variations in specific genes or developmental 412 pathways is partly due to the small data set we have (15 patients). The small sample size is no 413 problem for the de novo and our recessive model strategy in known disease genes, but it is so for the 414 heterozygous variant burden analysis. Another limitation is the lack of data on the expression of 415 genes involved in normal foregut development in human embryos. Our gene selection was based on 416 mouse transcriptome data. Little human data is available since human embryos of 4 to 6 weeks old 417 are generally not preserved. However, although it is unclear how precisely the foregut development 418 in mice corresponds with humans, it is unlikely that this is very different in its early phases. Finally, 419 one could argue that variations in the non-coding part of the genome are major contributors. 420
Although we did investigate known IHPS risk loci and determined genome wide CNV profiles, we did 421 not determine genome wide variation. which might contribute to disease development and although there is no difference in burden, some 430 variants might contribute more than others and this is not taken into account in a burden test. We might have misinterpreted the impact of some of the inherited variants. Furthermore, in some 432 patients the IHPS predisposing locus rs1933683 is present. 433
We hypothesized several multifactorial models in which the combination of multiple high impact The initial variant filtering method has been described previously (Halim et al., 2017) . In brief, we 461 included all variants with an allele frequency below 1% in 1000 Genomes phase 3 version 5, Exome 462
Variant Server 6500 v0.0.30, Genome of the Netherlands (Genome of the Netherlands, 2014), ExAC 463 (n=387) and Haloplex Exome target enrichment system (n=240), Agilent Technologies, Inc., Santa 466 Clara, California). 467
All nonsense variants, variants predicted to affect splicing and all variants with a Combined 468
Annotation-Dependent Depletion (CADD) score (Kircher et al., 2014) above 20 were selected for 469 individual patient analysis in downstream tools. Different downstream tools were used to prioritize 470 the variants. Prioritized variants were further classified according to the criteria in Table S8 . Using PhenIX the full patient phenotype in HPO terms was used, the exome target region filter is 505 on and allele frequency filter of 0.1%, pathogenicity filter was on and mode of inheritance unknown. 506
Genes were prioritized using PhenIX which compares patient phenotypes against human phenotypes 507 only. As a cut-of we used a gene relevance score of 0.8 in combination with a variant score of 0.8, or 508 a total score of 0.9. 509
When using the Exomiser tool we used similar settings: full patient phenotype in HPO terms, 510 exome target region filter is off, allele frequency filter 0.1%, pathogenicity filter on. We did not 511 remove dbSNP variants nor used an inheritance model. Genes are now prioritized using hiPhive, 512
which compares phenotypes against all species. As a cut-of we used a phenotype score of 0.8 in 513 combination with a variant score of 0.8, or an Exomiser score of 0.9. 514 515
Pathway enrichment analysis of genes affected by rare variants 516
To investigate if specific pathways are enriched with ultra-rare variants, Gene IDs with variants in 517 canonical splice sites (n=16), nonsense variants (n=21), protein altering inframe InDels (n=28) and 518 missense variants (n=557) were uploaded to Ingenuity pathway Analysis (Qiagen, Venlo, The 519 Netherlands). Additionally, a more stringent set was uploaded with loss of function variants, 520 predicted to be loss of function intolerant (PLI ≥0.9, n=4) and protein altering variants with a Z-score 521 ≥3 (n=44). 522 523
Expression of candidate genes 524
Candidate gene expression was determined at relevant developmental time points in human and 525 mouse. Gene expression of top-ranking genes derived from the burden analysis and individual 526 patient sample prioritizations were determined using datasets (GSE13040, GSE19873, GSE34278, 527 GSE15872, GSE43381) downloaded from the Gene Expression Omnibus (GEO) (Edgar et al., 2002) . 528
We used public data on mice on the endoderm, mesoderm and ectoderm at E8.25, foregut at E8.5 529 and esophagus, stomach, pyloric sphincter and intestine at E11.5-E18.5 530 
Detection of common SNP associated with IHPS 538
Genome-wide association studies (GWAS) revealed five loci highly associated with IHPS (rs11712066, 539 rs573872, rs29784, rs1933683 and rs6736913), pointing towards MBNL1, NKX2-5, BARX1 and EML4 540 as candidate genes (Feenstra et al., 2012, Everett and Chung, 2013, Fadista et al., 2019). Since 541 rs6736913 is a low frequency missense variant, we did not further analyze this SNP in our patients. 542
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